Bringing RNA Back, Mirna Gets $34.5M in Series C
By Catherine Shaffer
Wednesday, October 24, 2012
Amidst a venture capital climate that could most charitably be described as "tough" for early stage biotech, Mirna Therapeutics Inc., of Austin, Texas, completed a $34.5 million Series C financing led by Sofinnova Ventures, with New Enterprise Associates, Pfizer Ventures, Osage University Partners, Correlation Ventures and some existing investors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.